Fuller H B Co (FUL) · Oct 6, 2026 · New debt
$950M debt offering — $950M notes; 4.2x pro forma net debt-to-Adjusted EBITDA
H.B. Fuller’s new debt offering advances its AMS acquisition, but pro forma leverage reaches 4.2x and interest expense jumps materially.
H.B. Fuller is using acquisitions to shift its portfolio toward faster-growing, higher-margin specialty adhesives, with medical adhesives as a central growth platform. The already-announced AMS transaction is intended to expand that platform materially, including surgical adhesives, biosurgicals and medical device applications. This filing turns the acquisition strategy into a defined financing plan. H.B. Fuller has commenced a private offering of $950 million of senior unsecured notes due 2034. The proceeds will fund the AMS purchase, refinance other borrowings, and repay the company’s 4.000% notes due February 15, 2027. 〔0〕
| Metric | FUL standalone | AMS | Pro forma combined |
|---|---|---|---|
| Net revenue | $3.554B | $313M | $3.867B (Adjusted Statement of Operations Data) |
| Adjusted EBITDA | $656.5M | $69.2M | $713.5M (Other Financial Data) |
| Net debt / Adjusted EBITDA | — | — | 4.2x (Other Financial Data) |
| Interest expense | — | — | $217.7M (Other Financial Data) |
| Interest coverage | — | — | 3.3x (Other Financial Data) |
The strategic rationale is reinforced, but the financing makes the cost visible. AMS adds roughly $313 million of revenue and $69 million of adjusted EBITDA to the historical combination, but the proposed financing structure produces 4.2x pro forma net leverage and $217.7 million of annualized interest expense. The filing’s pro forma net income is only $100.3 million, reflecting the burden of acquisition-related adjustments and incremental interest. (Adjusted Statement of Operations Data)
The deal is advanced, not completed. The notes offering remains subject to customary conditions, and $450 million of the notes must be redeemed at par if the acquisition is not completed by the outside date. That structure reduces some failed-deal risk for noteholders, but it also confirms that closing and integration—not financing intent—remain the next execution hurdles.
The pro forma case is still management-built rather than reported performance. The filing says the information is unaudited, not prepared under Article 11 of Regulation S-X, and that historical results are not necessarily indicative of future operating results. 〔1〕
Bottom line: This is meaningful progress toward H.B. Fuller’s medical-adhesives expansion, but it also formalizes a heavily leveraged transaction. The strategic story moves forward; the financial flexibility story becomes more demanding until AMS delivers the expected earnings and synergies.
Notes closing and AMS acquisition completion by June 25, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!